Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 609

1.

How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

Vermeire S, Dreesen E, Papamichael K, Dubinsky MC.

Clin Gastroenterol Hepatol. 2019 Oct 4. pii: S1542-3565(19)31092-4. doi: 10.1016/j.cgh.2019.09.041. [Epub ahead of print] Review.

PMID:
31589978
2.

Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD).

Verstockt S, Verstockt B, Vermeire S.

Expert Opin Ther Targets. 2019 Oct 15:1-12. doi: 10.1080/14728222.2019.1677608. [Epub ahead of print]

PMID:
31587593
3.

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.

Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, Gloudemans AK, van 't Wout AB, Korf H, Vermeire S, Te Velde AA, Ponsioen CY, D'Haens GR, Verbeek JS, Geiger TL, Wildenberg ME, van den Brink GR.

Gut. 2019 Sep 10. pii: gutjnl-2019-318264. doi: 10.1136/gutjnl-2019-318264. [Epub ahead of print]

4.

Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.

Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M.

J Crohns Colitis. 2019 Aug 29. pii: jjz151. doi: 10.1093/ecco-jcc/jjz151. [Epub ahead of print]

PMID:
31504343
5.

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease.

Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR.

Clin Gastroenterol Hepatol. 2019 Aug 29. pii: S1542-3565(19)30921-8. doi: 10.1016/j.cgh.2019.08.046. [Epub ahead of print]

PMID:
31473359
6.

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S.

Gastroenterology. 2019 Aug 27. pii: S0016-5085(19)41247-X. doi: 10.1053/j.gastro.2019.08.027. [Epub ahead of print]

7.

Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors.

Brijs K, Miclotte I, Vermeire S, Darche V, Politis C.

Int J Oral Maxillofac Surg. 2019 Aug 27. pii: S0901-5027(19)31274-3. doi: 10.1016/j.ijom.2019.08.007. [Epub ahead of print]

8.

Expression Levels of 4 Genes in Colon Tissue Might be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases.

Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, Ferrante M.

Clin Gastroenterol Hepatol. 2019 Aug 22. pii: S1542-3565(19)30905-X. doi: 10.1016/j.cgh.2019.08.030. [Epub ahead of print]

9.

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M.

Inflamm Bowel Dis. 2019 Aug 10. pii: izz167. doi: 10.1093/ibd/izz167. [Epub ahead of print]

PMID:
31400283
10.

A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.

Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A.

Inflamm Bowel Dis. 2019 Aug 2. pii: izz144. doi: 10.1093/ibd/izz144. [Epub ahead of print]

PMID:
31372650
11.

Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.

Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Review.

PMID:
31352970
12.

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D.

United European Gastroenterol J. 2019 Jul;7(6):750-758. doi: 10.1177/2050640619841538. Epub 2019 Mar 24. Erratum in: United European Gastroenterol J. 2019 Aug;7(7):988.

13.

Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13.

Creyns B, Cremer J, Hoshino T, Geboes K, de Hertogh G, Ferrante M, Vermeire S, Ceuppens JL, Van Assche G, Breynaert C.

Sci Rep. 2019 Jul 11;9(1):10064. doi: 10.1038/s41598-019-46472-6.

14.

Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.

Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.

Gastroenterology. 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4.

15.

Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses.

Vieira-Silva S, Sabino J, Valles-Colomer M, Falony G, Kathagen G, Caenepeel C, Cleynen I, van der Merwe S, Vermeire S, Raes J.

Nat Microbiol. 2019 Jun 17. doi: 10.1038/s41564-019-0483-9. [Epub ahead of print]

PMID:
31209308
16.

New biologics and small molecules in inflammatory bowel disease: an update.

Sabino J, Verstockt B, Vermeire S, Ferrante M.

Therap Adv Gastroenterol. 2019 May 26;12:1756284819853208. doi: 10.1177/1756284819853208. eCollection 2019. Review.

17.

Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia.

Cremer A, Demetter P, De Vos M, Rahier JF, Baert F, Moreels T, Macken E, Louis E, Ferdinande L, Fervaille C, Dedeurwaerdere F, Bletard N, Driessen A, De Hertogh G, Vermeire S, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group.

Clin Gastroenterol Hepatol. 2019 Jun 13. pii: S1542-3565(19)30645-7. doi: 10.1016/j.cgh.2019.05.062. [Epub ahead of print]

PMID:
31202983
18.

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.

Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G.

Gastroenterology. 2019 Oct;157(4):997-1006.e6. doi: 10.1053/j.gastro.2019.05.067. Epub 2019 Jun 5.

PMID:
31175865
19.

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.

Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A.

Clin Gastroenterol Hepatol. 2019 May 22. pii: S1542-3565(19)30551-8. doi: 10.1016/j.cgh.2019.05.029. [Epub ahead of print]

PMID:
31128336
20.

Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease.

Bislenghi G, Wolthuis A, Van Assche G, Vermeire S, Ferrante M, D'Hoore A.

Expert Opin Biol Ther. 2019 Jul;19(7):607-616. doi: 10.1080/14712598.2019.1623876. Epub 2019 Jun 3.

PMID:
31121104
21.

Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease.

Coenen S, Weyts E, Geens P, Vermeire S, Ferrante M, Vanhaecht K, Van Assche G.

Scand J Gastroenterol. 2019 May;54(5):592-596. doi: 10.1080/00365521.2019.1616214. Epub 2019 May 18.

PMID:
31106617
22.

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.

Pouillon L, Vermeire S, Bossuyt P.

BMC Med. 2019 May 8;17(1):89. doi: 10.1186/s12916-019-1323-8. Review.

23.

Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.

Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, De Vos M, Van Moerkercke W, Rahier JF, Bossuyt P, Dutré J, Humblet E, Staessen D, Peeters H, Van Hootegem P, Louis E, Franchimont D, Baert F, Vermeire S; Belgian Inflammatory Bowel Disease Research and Development Group (BIRD group).

J Crohns Colitis. 2019 Apr 16. pii: jjz080. doi: 10.1093/ecco-jcc/jjz080. [Epub ahead of print]

PMID:
30989232
24.

Corrigendum.

Yang L, Tang S, Baker SS, Arijs I, Liu W, Alkhouri R, Lan P, Baker RD, Tang Z, Ji G, Rutgeerts P, Vermeire S, Zhu R, Zhu L.

Inflamm Bowel Dis. 2019 Apr 8. pii: izz023. doi: 10.1093/ibd/izz023. [Epub ahead of print] No abstract available.

PMID:
30958546
25.

Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.

Bossuyt P, Vermeire S, Bisschops R.

Gut. 2019 Apr 6. pii: gutjnl-2019-318235. doi: 10.1136/gutjnl-2019-318235. [Epub ahead of print] No abstract available.

PMID:
30954951
26.

Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply.

Verstockt B, Vermeire S, Ferrante M, Breynaert C.

Aliment Pharmacol Ther. 2019 Apr;49(8):1091-1092. doi: 10.1111/apt.15212. No abstract available.

PMID:
30920040
27.

Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis.

Vancamelbeke M, Laeremans T, Vanhove W, Arnauts K, Ramalho AS, Farré R, Cleynen I, Ferrante M, Vermeire S.

J Crohns Colitis. 2019 Sep 27;13(10):1351-1361. doi: 10.1093/ecco-jcc/jjz064.

28.

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades.

Moens A, Verstockt B, Machiels K, Bossuyt P, Verdonck A, Lagrou K, van Assche G, Vermeire S, Ferrante M.

Eur J Gastroenterol Hepatol. 2019 Jun;31(6):668-673. doi: 10.1097/MEG.0000000000001394.

PMID:
30839436
29.

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.

Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A.

J Crohns Colitis. 2019 Sep 27;13(10):1248-1256. doi: 10.1093/ecco-jcc/jjz050.

PMID:
30820530
30.

The human microbiome in health and disease: hype or hope.

Falony G, Vandeputte D, Caenepeel C, Vieira-Silva S, Daryoush T, Vermeire S, Raes J.

Acta Clin Belg. 2019 Apr;74(2):53-64. doi: 10.1080/17843286.2019.1583782. Epub 2019 Feb 27.

PMID:
30810508
31.

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.

Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W.

J Crohns Colitis. 2019 Sep 19;13(9):1227-1233. doi: 10.1093/ecco-jcc/jjz031.

32.

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S.

Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.

33.

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.

Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, Ferrante M.

J Crohns Colitis. 2019 Jul 25;13(7):864-872. doi: 10.1093/ecco-jcc/jjz008.

PMID:
30715258
34.

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.

Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, Breynaert C, Van Assche G, Vermeire S, Ferrante M.

EBioMedicine. 2019 Feb;40:733-742. doi: 10.1016/j.ebiom.2019.01.027. Epub 2019 Jan 24.

35.

Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.

Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, Ferrante M, Breynaert C.

Aliment Pharmacol Ther. 2019 Mar;49(5):572-581. doi: 10.1111/apt.15126. Epub 2019 Jan 20.

PMID:
30663072
36.

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, Van Lommel L, Schuit F, Van Assche G, Rutgeerts P, Ferrante M, Vermeire S, Arijs I, Cleynen I.

J Crohns Colitis. 2019 Jul 25;13(7):916-930. doi: 10.1093/ecco-jcc/jjz007.

PMID:
30657881
37.

Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial.

Roelandt P, Demedts I, Willekens H, Bessissow T, Braeye L, Coremans G, Cuyle PJ, Ferrante M, Gevers AM, Hiele M, Osselaer M, Tack J, Tejpar S, Ulenaers M, Van Assche G, Van Cutsem E, Van Gool S, Vannoote J, Vermeire S, Bisschops R.

Endoscopy. 2019 Mar;51(3):237-243. doi: 10.1055/a-0755-7471. Epub 2019 Jan 15.

PMID:
30646403
38.

Optimising infliximab induction dosing for patients with ulcerative colitis.

Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T.

Br J Clin Pharmacol. 2019 Apr;85(4):782-795. doi: 10.1111/bcp.13859. Epub 2019 Feb 10.

PMID:
30634202
39.

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.

J Pediatr Gastroenterol Nutr. 2019 Jun;68(6):847-853. doi: 10.1097/MPG.0000000000002265.

PMID:
30633108
40.

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.

Ther Drug Monit. 2019 Jun;41(3):317-324. doi: 10.1097/FTD.0000000000000601.

PMID:
30633088
41.

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease.

Verstockt B, Perrier C, De Hertogh G, Cremer J, Creyns B, Van Assche G, Ferrante M, Ceuppens JL, Vermeire S, Breynaert C.

Front Immunol. 2018 Dec 18;9:2983. doi: 10.3389/fimmu.2018.02983. eCollection 2018.

42.

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.

Van den Berghe N, Verstockt B, Tops S, Ferrante M, Vermeire S, Gils A.

J Gastroenterol Hepatol. 2019 Jul;34(7):1175-1181. doi: 10.1111/jgh.14584. Epub 2019 Jan 16.

PMID:
30589948
43.

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A.

AAPS J. 2018 Dec 18;21(1):10. doi: 10.1208/s12248-018-0282-x.

PMID:
30564993
44.

Evaluation of next-generation sequencing-based clonality analysis of T-cell receptor gamma gene rearrangements based on a new interpretation algorithm.

Nollet F, Vanhouteghem K, Vermeire S, Maelbrancke E, Emmerechts J, Devos H, Cauwelier B.

Int J Lab Hematol. 2019 Apr;41(2):242-249. doi: 10.1111/ijlh.12954. Epub 2018 Dec 8.

PMID:
30537135
45.

Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.

Yang L, Tang S, Baker SS, Arijs I, Liu W, Alkhouri R, Lan P, Baker RD, Tang Z, Ji G, Rutgeerts P, Vermeire S, Zhu R, Zhu L.

Inflamm Bowel Dis. 2019 Mar 14;25(4):722-731. doi: 10.1093/ibd/izy359.

PMID:
30517639
46.

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.

Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W.

Gastroenterology. 2019 Mar;156(4):946-957.e18. doi: 10.1053/j.gastro.2018.11.035. Epub 2018 Nov 23.

47.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. No abstract available.

48.

Vedolizumab in Refractory Microscopic Colitis: An International Case Series.

Rivière P, Münch A, Michetti P, Chande N, de Hertogh G, Schoeters P, Ferrante M, Vermeire S, Van Assche G.

J Crohns Colitis. 2019 Mar 26;13(3):337-340. doi: 10.1093/ecco-jcc/jjy169.

PMID:
30329034
49.

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.

Dierckx T, Verstockt B, Vermeire S, van Weyenbergh J.

J Crohns Colitis. 2019 Mar 26;13(3):389-394. doi: 10.1093/ecco-jcc/jjy162.

50.

No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts' Scoring System.

Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D'Hoore A, Laharie D, Ferrante M.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1643-1645. doi: 10.1016/j.cgh.2018.09.047. Epub 2018 Oct 4.

PMID:
30291910

Supplemental Content

Loading ...
Support Center